Angiotech starts EU trial for broader indication of Vascular Wrap
This article was originally published in Clinica
Pressing on with efforts to expand the potential market for its Vascular Wrap - a paclitaxel-eluting mesh - Angiotech Pharmaceuticals has begun a European trial of the device in dialysis patients with end-stage renal disease. The technology is currently awaiting EU approval for use in advanced peripheral arterial disease of the lower limbs. The 198-patient EU trial is assessing its use after surgical implantation with an ePTFE vascular graft in the upper extremity for haemodialysis vascular access; a control group of patients will receive the standard of care - an ePTFE vascular graft alone. A pivotal trial in the US is also underway for assessing the AV access indication. The Vancouver, Canada-based firm expects to use the EU trial data along with the US trial results to support a CE-mark submission.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.